Lv7
3214 积分 2021-10-12 加入
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
8天前
已完结
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
11天前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
18天前
已完结
Small Cell Lung Cancer: A Review
26天前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
1个月前
已完结
Adjuvant Alectinib in ALK -Rearranged NSCLC — Here and Now
1个月前
已完结
Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review
1个月前
已完结
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
1个月前
已完结
Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma
1个月前
已完结
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
1个月前
已完结
皖公网安备34019202002308
